Immunocore

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.